Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1961099
Disease: Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 		0.400 GeneticVariation disease BEFREE Yet, none of these T-ALLs had a clonal chromosome t(12;14) translocation that deleted Bcl11b indicating that Tcrδ translocations that inactivate a copy of Bcl11b promote transformation of Atm-deficient thymocytes. 25486566 2014
CUI: C1961099
Disease: Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 		0.400 AlteredExpression disease BEFREE Within the standard risk group of thymic T-ALL (n = 102), low BCL11b expression identified patients with an unexpected poor outcome compared to those with high expression (5-year OS: 20%, n = 18 versus 62%, n = 84, P < 0.01). 25023966 2014
CUI: C1961099
Disease: Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 		0.400 AlteredExpression disease BEFREE When highly efficient and specific BCL11B-935-siRNA was used to analyze the inhibition of BCL11B mRNA level in primary T-cell acute lymphoblastic leukemia (T-ALL) cells, similar result was obtained. 21756541 2011
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia 		0.080 Biomarker disease BEFREE We recently found that a unique subset of innate-like γδ T cells develops from the DN2a stage of the fetal thymus independently of the zinc-finger transcription factor B cell leukemia/lymphoma 11b (Bcl11b). 29091759 2017
CUI: C2004493
Disease: Leukemia, B-Cell
Leukemia, B-Cell 		0.040 Biomarker disease BEFREE We recently found that a unique subset of innate-like γδ T cells develops from the DN2a stage of the fetal thymus independently of the zinc-finger transcription factor B cell leukemia/lymphoma 11b (Bcl11b). 29091759 2017
CUI: C0020179
Disease: Huntington Disease
Huntington Disease 		0.030 AlteredExpression disease BEFREE We propose that sequestration and/or decreased expression of Bcl11b in HD is responsible, at least in part, for the dysregulation of striatal gene expression observed in HD and may contribute to the specificity of pathology observed in this disease. 18595722 2008
CUI: C0004096
Disease: Asthma
Asthma 		0.020 Biomarker disease BEFREE We found significantly decreased Bcl11b but increased IL-17A and TGF-β1 expression in patients with asthma and a strongly negative correlation between Bcl11b and these 2 cytokines in SA patients. 30088373 2018
CUI: C1961099
Disease: Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 		0.400 Biomarker disease BEFREE We describe a novel variant t(5;14) whereby NKX2-5, a related (NK-like family) homeobox gene located approximately 2 Mb telomeric of TLX3, juxtaposes BCL11B in a subset of T-cell ALL cell lines. 14500364 2003
CUI: C0002170
Disease: Alopecia
Alopecia 		0.010 Biomarker disease BEFREE We demonstrated that keratinocytic ablation of Ctip2 leads to atopic dermatitis (AD)-like skin inflammation, characterized by alopecia, pruritus and scaling, as well as extensive infiltration of immune cells including T lymphocytes, mast cells, and eosinophils. 23284675 2012
CUI: C3875321
Disease: Inflammatory dermatosis
Inflammatory dermatosis 		0.110 Biomarker disease BEFREE We demonstrated that keratinocytic ablation of Ctip2 leads to atopic dermatitis (AD)-like skin inflammation, characterized by alopecia, pruritus and scaling, as well as extensive infiltration of immune cells including T lymphocytes, mast cells, and eosinophils. 23284675 2012
CUI: C0011603
Disease: Dermatitis
Dermatitis 		0.010 Biomarker disease BEFREE We demonstrated that keratinocytic ablation of Ctip2 leads to atopic dermatitis (AD)-like skin inflammation, characterized by alopecia, pruritus and scaling, as well as extensive infiltration of immune cells including T lymphocytes, mast cells, and eosinophils. 23284675 2012
CUI: C0011615
Disease: Dermatitis, Atopic
Dermatitis, Atopic 		0.010 Biomarker disease BEFREE We demonstrated that keratinocytic ablation of Ctip2 leads to atopic dermatitis (AD)-like skin inflammation, characterized by alopecia, pruritus and scaling, as well as extensive infiltration of immune cells including T lymphocytes, mast cells, and eosinophils. 23284675 2012
CUI: C0013595
Disease: Eczema
Eczema 		0.010 Biomarker disease BEFREE We demonstrated that keratinocytic ablation of Ctip2 leads to atopic dermatitis (AD)-like skin inflammation, characterized by alopecia, pruritus and scaling, as well as extensive infiltration of immune cells including T lymphocytes, mast cells, and eosinophils. 23284675 2012
CUI: C1856266
Disease: Coronal craniosynostosis
Coronal craniosynostosis 		0.010 GeneticVariation disease BEFREE Using whole-genome sequencing, we identified a novel, de novo variant in BCL11B, c.7C>A, encoding an R3S substitution (p.R3S), in a male patient with coronal suture synostosis. 31067316 2019
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.090 GeneticVariation group BEFREE Two of these interstitial deletions (murine Notch1 and Bcl11b deletions) have been detected, at low frequency, in tissues from healthy mice with no evidence of malignancy, similar to the finding of chromosomal translocations in the peripheral blood or tonsils of healthy individuals. 22334400 2012
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.060 GeneticVariation group BEFREE Two of these interstitial deletions (murine Notch1 and Bcl11b deletions) have been detected, at low frequency, in tissues from healthy mice with no evidence of malignancy, similar to the finding of chromosomal translocations in the peripheral blood or tonsils of healthy individuals. 22334400 2012
CUI: C0023492
Disease: Leukemia, T-Cell
Leukemia, T-Cell 		0.020 AlteredExpression disease BEFREE Two different T-cell lines were forced to express BCL11B at levels similar to those observed in primary T-cell leukemias. 20824091 2010
CUI: C0456103
Disease: Sepsis of the newborn
Sepsis of the newborn 		0.010 Biomarker disease BEFREE TSPO, ZAP70, CEBPB targeting MAPK14, has-miR-150 targeting BCL11B might affect the pathogenesis of neonatal sepsis. 30497506 2018
CUI: C3665339
Disease: Bacterial sepsis of newborn
Bacterial sepsis of newborn 		0.010 Biomarker disease BEFREE TSPO, ZAP70, CEBPB targeting MAPK14, has-miR-150 targeting BCL11B might affect the pathogenesis of neonatal sepsis. 30497506 2018
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 Biomarker group BEFREE Together, our results argue that Bcl11b impairment promotes tumor development in mouse and human intestine at least in part through deregulation of β-catenin pathway. 25827435 2015
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia 		0.080 Biomarker disease BEFREE To screen the highly efficient and specific B-cell chronic lymphocytic leukemia/lymphoma 11B (BCL11B) small interfering RNA (siRNA) which are able to downregulate the BCL11B gene expression in human T-cell acute lymphoblastic leukemia, thereby inhibiting the leukemic T-cell proliferation and inducing apoptosis, four BCL11B-siRNAs and the scrambled non-silencing siRNA control (sc) were designed and obtained by chemosynthesis. 21756541 2011
CUI: C1868683
Disease: B-CELL MALIGNANCY, LOW-GRADE
B-CELL MALIGNANCY, LOW-GRADE 		0.020 Biomarker disease BEFREE To screen the highly efficient and specific B-cell chronic lymphocytic leukemia/lymphoma 11B (BCL11B) small interfering RNA (siRNA) which are able to downregulate the BCL11B gene expression in human T-cell acute lymphoblastic leukemia, thereby inhibiting the leukemic T-cell proliferation and inducing apoptosis, four BCL11B-siRNAs and the scrambled non-silencing siRNA control (sc) were designed and obtained by chemosynthesis. 21756541 2011
CUI: C0376545
Disease: Hematologic Neoplasms
Hematologic Neoplasms 		0.030 Biomarker group BEFREE To our knowledge, this is the first report implicating BCL11B in hematological malignancies. 15104287 2004
CUI: C0376545
Disease: Hematologic Neoplasms
Hematologic Neoplasms 		0.030 Biomarker group LHGDN To our knowledge, this is the first report implicating BCL11B in hematological malignancies. 15104287 2004
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.020 Biomarker disease BEFREE Thus, targeting the PDK1- and HOTAIR-mediated downstream molecule EZH2 by the combination of ATL-1 and erlotinib potentially facilitates the development of an additional novel strategy to combat lung cancer. 30223276 2018